TY - JOUR AU - Vishnupriya, R. AU - Ezhilramya, J. AU - Meenakshi, B. PY - 2016/04/01 Y2 - 2024/03/28 TI - METFORMIN IN THE PREVENTION OF METABOLIC SYNDROME ASSOCIATED WITH INITIATION OF ATYPICAL ANTIPSYCHOTIC THERAPY IN ADOLESCENTS AND YOUNG ADULTS - A RANDOMIZED, OPEN LABELLED, SINGLE CENTERED STUDY JF - International Journal of Pharmacy and Pharmaceutical Sciences JA - Int J Pharm Pharm Sci VL - 8 IS - 4 SE - Original Article(s) DO - UR - https://journals.innovareacademics.in/index.php/ijpps/article/view/10625 SP - 200-206 AB - <p><strong>Objective: </strong>The aim of the study was to evaluate the effectiveness and safety of Metformin along with Risperidone to prevent antipsychotic-induced metabolic syndrome in first-episode schizophrenia patients.<strong></strong></p><p><strong>Methods: </strong>This was a randomized, open labelled, prospective study conducted in the Department of psychiatry, Tirunelveli medical college. Around 96 patients diagnosed with first episode schizophrenia were randomized into 2 groups.<strong> </strong>Group 1 patients were given T. Risperidone (2 mg twice daily, n=48) and group 2 patients were given T. Metformin (500 mg twice daily, n=48) along with T. Risperidone for 6 mo.<strong></strong></p><p>The primary endpoint assessed was the proportion of patients developing metabolic syndrome at the end of 6 mo in both the groups. The secondary endpoints were the changes in body mass index (BMI), waist circumference (WC), fasting blood sugar (FBS) and triglycerides (TGL) from baseline to the end point.</p><p><strong>Results: </strong>There was a significant reduction in BMI and WC at the end of 3 mo (p&lt;0.001) and at the end of 6 mo (p&lt;0.001) when compared to baseline in group II individuals. There was a significant reduction in FBS and TGL levels at the end of 6 mo of treatment (p&lt;0.001) in group II individuals. There was the significant statistical difference between both the groups (p&lt;0.05) in terms of BMI, WC, FBS, triglycerides. The treatment emergent adverse effects with Metformin were generally mild and did not lead to any discontinuation.<strong></strong></p><p><strong>Conclusion: </strong>The use of Metformin along with Risperidone may have a better impact on the long-term cardiovascular morbidity and mortality of the schizophrenia patients. <strong></strong></p><p><strong>Keywords: </strong>Schizophrenia, Metabolic syndrome, Atypical antipsychotics, Body mass index, Waist circumference, Fasting blood sugar, Triglycerides<strong></strong></p> ER -